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THE role of the L-arginine-nitric oxide metabolic
pathway was explored for interleukin-2-induced
proliferation in the cytotoxic T lymphocyte clone
CTLL-2. Specific inhibition of nitric oxide
synthase significantly diminished, in a concentra-
tion-dependent manner, 3H-thymidine uptake of
CTLL-2 cells in response to different concentra-
tions of interleukin 2. Withdrawal of L-arginine
from culture medium resulted as potent as the
higher inhibition obtained when blocking nitric
oxide synthase with L-arginine analogues.
Furthermore, intermedial concentrations of L-
arginine and exogenous nitric oxide donors were
found for achieving optimal IL2-induced prolif-
eration of CTLL-2. These findings prompted us to
suggest that intra- and/or inter-cellular nitric
oxide signalling may contribute to the modula-
tion of the IL2 mitogenic effect upon cytotoxic T
lymphocytes.
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Introduction
Interleukin-2 (IL2) is among the principal lym-
phokines used in humans, either alone or in
combination with lymphokine-activated killer
cells, to treat advanced cancer. Its therapeutic
proficiency has been related with the clonal
expansion of a broad range of T cell types, but
particularly cytotoxic T lymphocytes.
2 However,
despite many efforts, most of the signal trans-
duction pathways involved in the IL2-induced
proliferation are yet to be elucidated.
Meanwhile, the induction of high nitric oxide
(NO) levels has been suggested as being respon-
sible for some of the adverse side effects of IL2
treatment,
3 and further findings have demon-
strated the beneficial effect of concomitant
administration of L-arginine for improving IL2-
induced immune stimulation.4
Two major nitric oxide synthases (NOS) have
been reported; the inducible (iNOS) mainly
dependent on inflammatory stimuli5 and the
constitutive (cNOS) controlled by calmodulin
and free Ca2+ concentrations.6’7 Both enzymes
are, in fact, capable of using L-arginine and
molecular oxygen as substrates for producing L-
citrulline and NO,
8 however, the distinguishable
characteristics of cNOS kinetic9 let it function
as an ubiquitous system for mediating the
generation of cGMP,7 whereas iNOS is princi-
pally associated with high output of NO for
killing invaders and/or injuring affected tissues.
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In this study we wanted to explore the role
of different levels of endogenous or exogenous
NO in the IL2-induced proliferation in a well-
known clone of cytotoxic T lymphocytes, the
CTLL-2 cell.
Materials and Methods
LNMMA (Wellcome Research Labs) and sodium
nitroprussiate (SNP) (Sigma) were freshly pre-
pared at (2 mM) in corresponding culture med-
ium and filtered through a 0.2 btm syringe filter
(Millipore), and finally added in volumes of
50 bWwell to final concentrations of 500, 50 or
5M and 500, 50, 5, 0.5, 0.05, 0.005 or
0.0005 bM respectively.
The CTLL-2 (IL2-dependent subclone of cyto-
toxic T cells derived from a C57bl/6 mouse)
were obtained from Dr M. Arafia at the Center
of Biological Research, Havana, Cuba. Cells
were grown .at 37C and 5% of CO2 in RPMI
1640 (ICN Flow) supplemented with streptomy-
cin (100 >g/ml) (Gibco), penicillin (100 U/ml)
(Gibco), L-glutamine (2 mM) (Gibco), 10% of
heat-inactivated fetal calf serum (Gibco), 20% of
T cell growth factor (Wellcome Research Labs)
and 2 mercapto-ethanol (5 bM) (Sigma).
Prior to experimentation, cells were washed
twice in fresh RPMI 1640 and later suspended
(1 106 cells/ml) in the same culture medium
used for maintenance but without T cell growth
factor. Cell suspension was then plated at
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1 105 cell/well and pretreated for 30min
with L-NMMA or SNP, and finally stimulated
with IL2 (Dinatec) in volumes of 50 bWwell to
final concentrations of 20, 10 or 5 U/ml.
In order to analyse the effect of L-arginine on
the IL2-induced proliferation, cells were
washed, plated and treated as described above,
but in RPMI 1640 free from L-arginine (ICN
Flow) instead of normal RPMI 1640. The sup-
plement of L-arginine (ICN Flow) was adjusted
to different concentrations by diluting in L-
arginine free RPMI 1640, and finally added in
volumes of 50 >l/well.
The proliferation of CTLL-2 was assumed to be
a function of the counts per minute (cpm) of the
DNA fraction after incubation for the last 8-12 h
of culture with 1 bCi of 3H-thymidine (Amer-
sham) (added in volumes of 25 bWwell). All
plates were frozen until harvested and counted
for 60 s on a liquid scintillation counter.
The measurement of nitrite was based on the
reaction of equal volumes of sample and Griess
reagent, which briefly consists of a mixture of 0t
naphtyl amine at 0.1% in water and sulphanil-
amide at 1% in phosphoric acid at 5% (1:1 v/v).
After 10 min light absorbance was measured at
540 nm.
All data are expressed as mean-+-standard
error from at least three experiments each with
three replicates. Comparison between groups
was based on Student’s t-test and significant
difference was accepted as p < 0.05.
Results
A normal curve of CTLL-2 growth in the
presence of different concentrations of IL2 was
clearly evident after 24 h of culture (Fig. 1).
Additionally, it was also observed that in all
cases administration of the specific NOS antago-
nist LNMMA (500 bM) was capable of signifi-
cantly diminishing 3H-thymidine uptake. Similar
results were obtained in previous experiments
when T cell growth factor was used instead of
IL2 (data not shown).
Further results (Fig. 2) demonstrated that, in
the presence of L-arginine (0.1 mM) and fixed
concentration of IL2 (20 U/ml), the specific
NOS antagonist LNMMA showed a concentra-
tion-dependent inhibitory effect upon CTLL-2
growth. However, in the absence of L-arginine,
H-thymidine uptake in all cases remained at a
basal plateau resembling that observed when
treated with LNMMA (500 bM).
Consistently (Fig. 3), when different concen-
trations of L-arginine were assayed for CTLL-2
H-thymidine uptake in the presence of fixed
concentration of IL2 (5 U/ml), it was noted that
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FIG. 1. Proliferation profile of CTLL-2 cells after 24h of
cultures in responses to different concentrations of IL2, in
absence (open circles) or presence (solid circles) of LNMMA
at 500 #M. Each point is the mean-t-SEM of three experi-
ments. Equation of the linear regression curve is also
expressed on each case.
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FIG. 2. Concentration-dependent inhibitory effect of L-
NMMA upon IL2 (20 U/ml)-induced proliferation on CTLL-2
cells, in presence (2 mM) (open circles) or absence (solid
circles) of L-arginine. The absence of L-arginine was as
potent as L-NMMA (500#M) for reducing CTLL-2 cells
proliferation. Each point is the mean 4- SEM of three experi-
ments. Equation of the linear regression curve is also
expressed on each case.
there was maximal proliferation at around
0.3 mM. Either very low or very high levels of L-
arginine had significantly lower values of H-
thymidine uptake.
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FIG. 3. Concentration-dependent modulatory effect of L-
arginine upon the proliferation induced by IL2 (5 U/ml) on
CTLL-2 cells. Each point is the mean -t-SEM of three
experiments. Student’s t-test was assessed vs baseline.
Significant difference was accepted for * p < 0.05.
Finally, it was observed that even exogenous
administration of NO was able to modulate the
proliferation of CTLL-2 cells in response to IL2
(5 U/ml) (Fig. 4). A well-known NO generator
(SNP) was added in a wide range of concentra-
tions and, as with L-arginine, there seems to
exist a critical value of concentration of NO
(around 20 pmol/ml) for which the proliferation
was maximal. Either lower or higher levels of
NO may affect the optimal proliferation of
CTLL-2 cells.
Discussion
The involvement of NO in the control of the
mitogenic activation of T cells was firstly
described in models of whole spleen cells
proliferation in response to Con A.
1 In that
case it was assumed that the NO coming from
the co-cultured activated macrophages might be
functioning as a suppressor mechanism to
downregulate T cells growth. Further studies,
however, reported the finding that the NO
metabolic pathway was essential for the normal
DNA synthesis in purified lymphocytes growing
in response to Con A.
11 Such apparent contra-
diction could be basically explained because of
the level and localization of NO generation, but
it may be important to also consider the T cell
type.
Indeed, different patterns of production and
susceptibility to NO for two clones of T helper
24
"
20-
O
x 18
16
14
.- ]2
"
0
8
6-
//
0.0oo0o 100 0.001 0.01 0.1 10
NO2- from SNP (M)
FIG. 4. Concentration-dependent modulatory effect of the
SNP-derived NO upon proliferation of CTLL-2 cells in
response to IL2 (5 U/ml). The stable metabolite nitrite was
measured as index of NO generation from SNP. Each point
is the mean 4-SEM of three experiments. Student’s t-test
was assessed vs baseline. Significant difference was ac-
cepted for * p < 0.05.
type 1 (Thl) and T helper type 2 (Th2)
lymphocytes have been described.
12 The first
seem to be potent generators of NO but at the
same time they are susceptible to diminishing
their own cytokine production and growth
when high NO levels occur, meanwhile the
second do not produce and remain apparently
unaffected to high NO levels.
Curiously CTLL-2 cells in our system failed to
generate high NO levels as a final effector
molecule after IL2 activation (data not shown).
It might be thought that NO is actually not
important for their cytotoxicity or for the full
activation of CTLL-2 further stimuli are required,
such as close contact with target cells or
combination with other cytokines or humoral
factors.
In any case it is interesting that CTLL-2 cells
may be using its production of low levels of
NO13 as an intracellular signal transduction
pathway for the IL2-induced proliferation, with-
out excluding that, when high NO level occurs,
a typical negative feed-back mechanism down-
regulate their own growth. It should be impor-
tant to note that exogenous NO may also
modulate the IL2-induced proliferation on CTLL-
2, suggesting that even the NO generated by
surrounding cells might be actively contributing
to the modulation of cytotoxic T lymphocytes
proliferation.
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Considering that for macrophages such de-
pendence on low levels of NO for cGMP
generation during activation is also probable
14
meanwhile high NO levels mediate its own
programmed cell death,
15 it is possible to
speculate that the NO metabolic pathway is not
only differentially produced as a final effector
molecule from a wide range of immune cells,
but might also represent an additional humoral
factor (beside cytokines) for modulating inter-
cellular induced activation, growth and death.
The present report gives new evidence of the
roles of the L-arginine-NO metabolic pathway
for understanding the pharmacodynamics of IL2
therapy. Appropriately low levels of NO may
guarantee clonal expansion of cytotoxic T
lymphocytes encouraged for killing infected or
transformed cells, but high NO levels may also
inhibit mitogenic effects of IL2. Thus, an im-
provement on IL2 therapy might be possible by
controlling the appropriate levels of L-arginine
and/or NO. In that sense, new NO scavengers
and/or novel isoform specific NOS inhibitors
may represent valuable approaches.
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